Key Points
- Tobin Juvenal, an insider at Castle Biosciences, sold 20,863 shares on March 12 at an average price of $25.24, a $526,582 transaction that reduced his holding by 19.37% to 86,825 shares.
- Castle recently beat quarterly expectations with EPS of -$0.08 versus -$0.23 expected and revenue of $81.88M, and analysts maintain a consensus "Moderate Buy" with an average target of $47.57.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Tobin Juvenal sold 20,863 shares of the business's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $25.24, for a total transaction of $526,582.12. Following the sale, the insider owned 86,825 shares in the company, valued at $2,191,463. The trade was a 19.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Castle Biosciences Stock Performance
Shares of CSTL opened at $25.83 on Tuesday. The company has a 50-day simple moving average of $34.37 and a 200-day simple moving average of $31.77. The company has a quick ratio of 5.11, a current ratio of 5.26 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $767.93 million, a PE ratio of -30.39 and a beta of 1.09. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $44.28.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.15. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. The firm had revenue of $81.88 million during the quarter, compared to analysts' expectations of $81.19 million. Equities research analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. Guggenheim boosted their price target on Castle Biosciences from $43.00 to $47.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Robert W. Baird raised their price objective on Castle Biosciences from $41.00 to $44.00 and gave the company an "outperform" rating in a research note on Friday, February 27th. BTIG Research lifted their price objective on Castle Biosciences from $38.00 to $50.00 and gave the stock a "buy" rating in a report on Friday, December 12th. Zacks Research downgraded Castle Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 2nd. Finally, Canaccord Genuity Group upped their target price on Castle Biosciences from $37.00 to $50.00 and gave the company a "buy" rating in a report on Monday, December 22nd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Castle Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $47.57.
Check Out Our Latest Research Report on Castle Biosciences
Institutional Trading of Castle Biosciences
Several institutional investors and hedge funds have recently modified their holdings of the business. Federated Hermes Inc. acquired a new stake in shares of Castle Biosciences in the fourth quarter valued at approximately $26,000. Farther Finance Advisors LLC raised its position in shares of Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company's stock worth $32,000 after purchasing an additional 1,391 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Castle Biosciences during the 3rd quarter worth approximately $35,000. Kemnay Advisory Services Inc. purchased a new stake in Castle Biosciences in the 4th quarter valued at approximately $35,000. Finally, CWM LLC grew its holdings in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company's stock valued at $44,000 after buying an additional 853 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
